@GarciaOlmoD @Hospital_FJD @VillarejoCampos @h_guadalajara @aecirujanos Enhorabuena @VillarejoCampos !👏
#BCG Unresponsive & unsuitable or unwilling for radical cystectomy?
#HIVEC
“We report a median DFS of 17.7 months potentially avoiding or postponing the need for radical surgery in a proportion of these patients”
#BladderCancer #NMIBC #BladderSparing
Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients - PubMed
HIVEC® seems a valid treatment option for BCG unresponsive NMIBC patients. We report a median DFS of 17.7 months (SE 6.72), potentially avoiding or p...
pubmed.ncbi.nlm.nih.gov
With our partner @MedenInmed at the University Hospital in Fuenlabrada (Madrid); Prof.Murawa and Dr.Cieciorowski watching CRS + PRS HIPEC cases @CombatCancer #HIPEC #PRS
@CombatCancer participará con un stand virtual en el Workshop de GECOP @operaelcancer organizado por el Dr.Fernando Pereira del HU Fuenlabrada los días 10 y 11 de Junio - visítenos y recibirá más información acerca de #HIPEC con la técnica cerrada y agitada PRS+Agitación por CO2
@CombatCancer participará con un stand virtual en el Workshop de GECOP @operaelcancer organizado por el Dr.Fernando Pereira del HU Fuenlabrada los días 10 y 11 de Junio - visítenos y recibirá más información acerca de #HIPEC con la técnica cerrada y agitada PRS+Agitación por CO2
@3speeders @NorthBristolNHS @BladderCancerUK Good luck with your treatment!
#BCGUnresponsive
IBCG - “a clinically meaningful complete response rate for CIS at least 50% at 6m, 30% at 12m..is recommended”
#HIVEC in BCGU
70% CR @ 3m
>50% CR @ 6m
STILL 50% CR @ 12m
https://tinyurl.com/5arewevc
#BladderCancer
#BladderCancerAwarenessMonth
Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
To provide recommendations on appropriate clinical trial designs in non–muscle-invasive bladder cancer (NMIBC) based on current literature and exper...
tinyurl.com
🇵🇱First successful Combat PRS+A-HIPEC Cases after CRS done at the Lower Silesian Oncology Institute in Wroclaw last week🇵🇱 with our local partner Meden-Inmed Sp. z o.o.!
Many thanks to Prof.Dr.Bebenek and his team for the opportunity.@CombatCancer @ESSOnews @operarelcancer #HIPEC
Great results from our friends @DukeUrology on the use of HIVEC in the USA.
“HIVEC is a safe and well-tolerated substitute for BCG during global shortages”
👏🏻👏🏻👏🏻 @DominicGrimberg @BrantInman
#BladderCancer #Cancer #HIVEC
https://www.sciencedirect.com/science/article/abs/pii/S1078143920306542
Intravesical hyperthermia with high-dose mitomycin-C shows promise as BCG alternative for NMIBC
"Our study demonstrates the feasibility of HIVEC MMC and suggests it is a reasonable substitute for BCG during global shortages," says urologist Scott...
www.urologytimes.com
Great results from our friends @DukeUrology on the use of HIVEC in the USA.
“HIVEC is a safe and well-tolerated substitute for BCG during global shortages”
👏🏻👏🏻👏🏻 @DominicGrimberg @BrantInman
#BladderCancer #Cancer #HIVEC
https://www.sciencedirect.com/science/article/abs/pii/S1078143920306542
Intravesical hyperthermia with high-dose mitomycin-C shows promise as BCG alternative for NMIBC
"Our study demonstrates the feasibility of HIVEC MMC and suggests it is a reasonable substitute for BCG during global shortages," says urologist Scott...
www.urologytimes.com
More great news for Combat’s #HIVEC treatment of #bladdercancer from @BrantInman and team at @ASCO meeting.
“Bladder pressure dramatically improves the extent of gemcitabine penetration into the bladder wall”
https://meetinglibrary.asco.org/record/194854/abstract
Many thanks to the team @DukeUrology 👏🏻👏🏻👏🏻
Excellent to hear this. So happy our machine is working to treat patients in Bristol. @CombatCancer #HIVEC #bladdercancer @NorthBristolNHS
Here I go again, this treatment is amazing and I’m so grateful to @NorthBristolNHS #urology for providing this ‘maintenance’ #bladdercancer @CombatCancer @Actionbladderca
Here I go again, this treatment is amazing and I’m so grateful to @NorthBristolNHS #urology for providing this ‘maintenance’ #bladdercancer @CombatCancer @Actionbladderca
@alarjosan @HUReinaSofia @IMIBIC @GECOP_ @operarelcancer @SPeritoneum @aecirujanos @ESSOnews @Hospital_FJD Congrats @alarjosan and team!
Proud to be working with you!
👏🏻👏🏻👏🏻👏🏻👏🏻
40 patients took part in the study, split into two groups – one which received the HIVEC™ treatment prior to a resection of the bladder, and another which received HIVEC after resection of the bladder.
97% of the patients were able to complete the full course of HIVEC treatments, and the majority of participants responded well to the treatment and show low rates of recurrence. Furthermore, the majority of the side-effects were low grade and had very little effect on the treatment plan.
Click Here to read the full article
Click Here to read the interview with the research author
